Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
A lack of consensus guidelines or a belief that current evidence does not support such guidelines might be justified if a clinician expresses a commitment to patient-centered care and shared decision making.
AMA J Ethics. 2018;20(11):E1007-1016. doi:
10.1001/amajethics.2018.1007.
In the 1910s, the American Medical Association fought quackery promoted in pamphlets for drugs and treatments for everything from teething to epilepsy.
AMA J Ethics. 2018;20(11):E1082-1093. doi:
10.1001/amajethics.2018.1082.
AMA Journal of Ethics theme editor Terri Davis, a third-year MD student at West Virginia University School of Medicine, interviewed Ranit Mishori, MD, about how to respond to incidents of suspected human trafficking in health care settings.
Although identical twin-to-twin skin grafting has resulted in excellent survival rates in burn patients, the nature and scope of ethical decision making in monozygotic sibling skin grafting needs further examination.
AMA J Ethics. 2018;20(6):537-545. doi:
10.1001/journalofethics.2018.20.6.cscm2-1806.
Public health surveillance for infectious disease provides a model for a mandatory reporting policy for human trafficking, which poses risks for survivors.
AMA J Ethics. 2017;19(1):45-53. doi:
10.1001/journalofethics.2017.19.1.stas1-1701.